T. Rowe Price Associates Portfolio holdings
T. Rowe Price Associates, Inc., founded in 1937 by Thomas Rowe Price, Jr., is a globally recognized investment management firm headquartered in Baltimore, Maryland, known for its disciplined, research-driven approach to active investing. The company manages hundreds of billions in assets, offering a wide range of mutual funds, retirement plans, and advisory services tailored to individual investors, institutions, and financial intermediaries. Emphasizing long-term growth and a conservative investment philosophy, T. Rowe Price has built a strong reputation for its equity and fixed-income funds, often focusing on fundamental analysis to identify undervalued opportunities. Still publicly traded and independent, it remains a trusted name in the industry, balancing tradition with innovation to meet evolving client needs.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
AGN
Allergan Inc
AGN
|
+$1.3B |
| 2 |
American Airlines Group
AAL
|
+$853M |
| 3 |
Intuitive Surgical
ISRG
|
+$816M |
| 4 |
Morgan Stanley
MS
|
+$681M |
| 5 |
Wynn Resorts
WYNN
|
+$622M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Procter & Gamble
PG
|
+$1.4B |
| 2 |
eBay
EBAY
|
+$763M |
| 3 |
DISCK
Discovery, Inc. Series C Common Stock
DISCK
|
+$760M |
| 4 |
Broadcom
AVGO
|
+$757M |
| 5 |
US Bancorp
USB
|
+$686M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 16.95% |
| 2 | Consumer Discretionary | 13.63% |
| 3 | Financials | 12.8% |
| 4 | Industrials | 12.27% |
| 5 | Technology | 9.96% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1626
W.R. Berkley
WRB
$26.2B
| $1.48M | ﹤0.01% |
108,030
-22,275
| -17% | -$290K |
|
1627
Crown Holdings
CCK
$12.9B
| $1.47M | ﹤0.01% |
29,550
-200
| -0.7% | -$9.59K |
|
1628
Sonoco
SON
$5.76B
| $1.47M | ﹤0.01% |
33,387
-7,200
| -18% | -$304K |
|
1629
Service Corp International
SCI
$11.5B
| $1.47M | ﹤0.01% |
70,731
+5,800
| +9% | +$113K |
|
|
PL
1630
DELISTED
PROTECTIVE LIFE CORP
PL
| $1.46M | ﹤0.01% |
21,113
+289
| +1% | +$16.5K |
|
1631
iShares MSCI United Kingdom ETF
EWU
$4.13B
| $1.46M | ﹤0.01% |
34,950
+10,150
| +41% | +$434K |
|
|
AL
1632
DELISTED
Air Lease Corp
AL
| $1.45M | ﹤0.01% |
37,583
+16,883
| +82% | +$646K |
|
1633
W.P. Carey
WPC
$16.3B
| $1.43M | ﹤0.01% |
22,666
| – | – |
|
1634
Timken Company
TKR
$9.25B
| $1.43M | ﹤0.01% |
29,337
| – | – |
|
|
UN
1635
DELISTED
Unilever NV New York Registry Shares
UN
| $1.42M | ﹤0.01% |
32,349
| – | – |
|
|
DHC
1636
Diversified Healthcare Trust
DHC
$2.03B
| $1.41M | ﹤0.01% |
58,738
| – | – |
|
1637
Atmos Energy
ATO
$28.7B
| $1.41M | ﹤0.01% |
26,460
| – | – |
|
|
METR
1638
DELISTED
METRO BANCORP, INC COMMON STOCK
METR
| $1.41M | ﹤0.01% |
60,900
| – | – |
|
|
SPLK
1639
DELISTED
Splunk Inc
SPLK
| $1.41M | ﹤0.01% |
25,400
+7,500
| +42% | +$394K |
|
|
SVC
1640
Service Properties Trust
SVC
$1.05B
| $1.39M | ﹤0.01% |
9,194
+504
| +6% | +$73.6K |
|
|
XLS
1641
DELISTED
EXELIS INC COM STK
XLS
| $1.38M | ﹤0.01% |
87,287
+3,321
| +4% | +$54.8K |
|
|
STML
1642
DELISTED
Stemline Therapeutics, Inc.
STML
| $1.37M | ﹤0.01% |
93,192
-737,074
| -89% | -$11.3M |
|
1643
Marvell Technology
MRVL
$199B
| $1.37M | ﹤0.01% |
95,300
-1,166,000
| -92% | -$17.9M |
|
1644
Owens Corning
OC
$12.2B
| $1.36M | ﹤0.01% |
35,200
+2,500
| +8% | +$103K |
|
1645
MSC Industrial Direct
MSM
$6.91B
| $1.36M | ﹤0.01% |
14,200
-3,500
| -20% | -$318K |
|
|
SFG
1646
DELISTED
STANCORP FINL GRP
SFG
| $1.36M | ﹤0.01% |
21,200
-1,400
| -6% | -$87K |
|
|
OA
1647
DELISTED
Orbital ATK, Inc.
OA
| $1.34M | ﹤0.01% |
10,025
+500
| +5% | +$69K |
|
1648
Avient
AVNT
$4.25B
| $1.33M | ﹤0.01% |
31,530
| – | – |
|
1649
Provident Financial
PROV
$113M
| $1.32M | ﹤0.01% |
91,100
| – | – |
|
1650
Gaming and Leisure Properties
GLPI
$12.7B
| $1.32M | ﹤0.01% |
38,862
+11,600
| +43% | +$405K |
|
Similar funds
T. Rowe Price Associates's Q2 2014 Portfolio in Review
As of Q2 2014, T. Rowe Price Associates held 2,596 positions worth $463B, up 3.9% from $445B the previous quarter. Its ten largest holdings account for 12% of the portfolio.
T. Rowe Price Associates's Q2 2014 filing shows 97 new, 1,091 increased, 793 reduced and 67 closed positions. Its largest new stake was Teva Pharmaceuticals: 4,638,481 shares worth $243M. The largest sale was Procter & Gamble, an estimated $1.4B.
By sector, the portfolio is most concentrated in Healthcare at 17% of assets, up from 16% a quarter earlier, followed by Consumer Discretionary and Financials.
- T. Rowe Price Associates's largest Q2 2014 buy was Teva Pharmaceuticals: 4,638,481 shares worth $243M.
- T. Rowe Price Associates added most to Allergan Inc in Q2 2014, an estimated $1.3B increase.
- T. Rowe Price Associates's biggest Q2 2014 reduction was Procter & Gamble, cutting an estimated $1.4B.
- T. Rowe Price Associates fully exited Santander in Q2 2014, selling an estimated $134M.
- T. Rowe Price Associates's ten largest holdings make up 12% of its $463B portfolio in Q2 2014.
- T. Rowe Price Associates opened 97 new positions and closed 67 in Q2 2014.
- T. Rowe Price Associates's portfolio value rose 3.9% quarter-over-quarter to $463B.
Based on T. Rowe Price Associates's 13F filing for Q2 2014, filed 14 Aug 2014.